Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study

Table 2

Existing risk factors for the occurrence of certain adverse events (except age > 65 years or weight > 100 kg), according to the investigators’ opinion.

Risk factors	Number of patients (%)
Total of patients with at least one risk factor	28/46 (60.9)
Dyslipidemia and/or hypercholesterolemia	14 (50.0)
Hypertension	11 (39.3)
Monoclonal gammopathy	6 (21.4)
Diabetes	4 (14.3)
Myocardial infarction	3 (10.7)
Migraine	2 (7.1)
Venous thromboembolic disease	2 (7.1)
Dyspnea	2 (7.1)
Chronic renal	1 (3.5)
Coronary insufficiency	1 (3.5)
Other risk	8 (3.5)

factors mentioned by some investigators. chronic renal impairment with blood creatinine at 103 μmol/L during the Tegeline last cycles administered in hospital.